#reatapharmaceuticals
Photo
FDA’s approval of Friedreich’s ataxia drug is a game changer for treatment of rare diseases
A drug to treat a rare neurological disorder has only had to jump through one hoop—read: clinical trial—instead of the recommended two to win regulatory approval.Read more...
https://qz.com/fda-approval-friedreich-s-ataxia-drug-reata-skyclarys-1850171937
#rarediseases#ataxia#skyclarys#biogen#reatapharmaceuticals#brianskorney#pharmaceuticalindustry#clinicaltrial#mauryraycroft#health2cmedical2cpharma#peterstein#foodanddrugadministration#reatae28099schronickidneydiseasedrug#friedreich27sataxia#health#unitedstatespublichealthservice#billydunn#warrenhuff#Ananya Bhattacharya#Quartz
0 notes
Photo
ReataPharmaceuticals @ReataPharma We’re happily celebrating @KidneyPatients 50th Anniversary in Washington, D.C at the AAKP National Patient Meeting. AAKP’s legacy of engagement and advocacy has helped more than a million kidney patients. A huge congrats to this organization! #KidneyPatients19 (at Hyatt Regency Washington DC) https://www.instagram.com/p/B2PV72mAn3u/?igshid=1l1vemh9bplqy
0 notes
Text
Do you know someone with Alport Syndrome? CARDINAL a research study is now enrolling patients with Alport syndrome! For more info visit https://t.co/M2ghwOLcxh #alportsyndrome pic.twitter.com/4tEoQRWH9c
— ReataPharmaceuticals (@ReataPharma) February 5, 2018
1 note
·
View note
Link
0 notes
Text
We are in New Orleans @ASNKidney meeting, presenting on CARDINAL Phase 2 (Block et al. abstract 2830903) #alportsyndrome #KidneyWk pic.twitter.com/zQRgzE6YSC
— ReataPharmaceuticals (@ReataPharma) November 2, 2017
0 notes
Text
Reata announces late-breaking presentation of primary results from Phase 2 CARDINAL Study at ASN #KidneyWk 2017 https://t.co/tFcAHKkjiq pic.twitter.com/tlUZAozY15
— ReataPharmaceuticals (@ReataPharma) October 20, 2017
0 notes
Text
Do you have Alport syndrome? You may be eligible to participate in a clinical trial! https://t.co/Rqghz3yl3d pic.twitter.com/xyDQNoyo1i
— ReataPharmaceuticals (@ReataPharma) October 9, 2017
0 notes
Text
Reata is proud to sponsor the @AlportSyndFndn family meeting in Minneapolis this weekend! Visit https://t.co/cZ3qYpqr3H to learn more. pic.twitter.com/K26eDGXcDN
— ReataPharmaceuticals (@ReataPharma) October 7, 2017
0 notes
Text
Reata Announces First Patient Enrolled in Phase 3 Trial of Bardoxolone Methyl in Treatment of #AlportSyndrome https://t.co/uhNRpkrg0D pic.twitter.com/EE5G6QML9p
— ReataPharmaceuticals (@ReataPharma) August 8, 2017
0 notes
Text
Join our conference call with management to learn more about our Phase 2 CARDINAL data #AlportSyndrome https://t.co/bzix9SCk0b pic.twitter.com/kKsGs1Xlds
— ReataPharmaceuticals (@ReataPharma) July 24, 2017
0 notes
Text
Bard demonstrated improved kidney function in patients with #AlportSyndrome in Phase 2 portion of CARDINAL study https://t.co/aUT0ffwVSV pic.twitter.com/puhVPhLWNv
— ReataPharmaceuticals (@ReataPharma) July 24, 2017
0 notes
Text
Reata Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of #AlportSyndrome https://t.co/6QIQf0JVzL pic.twitter.com/ptFPjR2y6H
— ReataPharmaceuticals (@ReataPharma) July 10, 2017
0 notes
Text
Visit our poster (MP142) at @ERAEDTA today to learn about the CARDINAL study for #AlportSyndrome pic.twitter.com/wnDwsuOIJp
— ReataPharmaceuticals (@ReataPharma) June 5, 2017
0 notes
Text
We are at @ERAEDTA June 3-6. Come see our poster MP142 on CARDINAL study in #AlportSyndrome on June 5!
— ReataPharmaceuticals (@ReataPharma) June 3, 2017
0 notes
Text
Visit Reata at Booth 249 at @PASMeeting to learn about the CARDINAL Study for #AlportSyndrome @ASPNeph @AlportSyndFndn pic.twitter.com/dobk0QRSXw
— ReataPharmaceuticals (@ReataPharma) May 6, 2017
0 notes
Text
March is Alport Syndrome Awareness Month! Find out more about Alport Syndrome from @AlportSyndFndn at https://t.co/cZ3qYpqr3H. pic.twitter.com/hyNsYnFOkX
— ReataPharmaceuticals (@ReataPharma) March 29, 2017
0 notes
Last Seen Blogs
cyberslovan
dhawan stan
wifiwivey
wifiwivey
cultureinparis-blog
Axelle Emden
enchantresssworld
ENCHANTRESS
cuntroach
Untitled